Premier Biotech Acquires NexScreen and TransMed
June 18, 2026
Align Capital Partners-backed Premier Biotech announced the acquisitions of NexScreen and TransMed to expand its product portfolio, e-commerce capabilities, and global footprint. NexScreen adds point-of-care diagnostic testing presence in Australia and New Zealand, while TransMed strengthens Premier’s catalog and online distribution to 1,000+ direct customer accounts.
- Targets
- NexScreen, TransMed
- Sellers
- John Debrovner (CEO of NexScreen), Ted Bernhardt (owner of TransMed)
- Platforms
- Premier Biotech
- Industry
- Healthcare Services
- Location
- Minnesota, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.